|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although SGP-2 transcripts, and hence pTB16, were recently shown to be increased in neurodegenerative diseases such as scrapie in hamsters and Alzheimer disease in humans, our observations with brain tumors and epilepsy are suggestive of a role for pTB16 in neuropathologies in general and support the hypothesis of its involvement in tissue remodeling and cell death.
|
1924317 |
1991 |
|
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
TRPM-2/clusterin is induced de novo during the regression of the prostate and other hormone-dependent tissues after hormone ablation, and is over-expressed in several human neurodegenerative diseases including Alzheimer's disease, epilepsy and retinitis pigmentosa.
|
8181474 |
1994 |
|
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
These results suggest a compensatory induction of apoJ (clusterin) in the brain of apoE4 AD subjects showing low brain levels of apoE.
|
8774959 |
1995 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
At the population level, APOJ/CLI polymorphisms are frequent among persons of African descent, but probably do not alter susceptibility to AD.
|
8792817 |
1996 |
|
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Clusterin/apoJ is an intriguing gene frequently isolated by differential screening in laboratories from different areas of molecular biology, since it is overexpressed in numerous cases of degenerative diseases such as Alzheimer's disease and scrapie.
|
9359832 |
1997 |
|
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
No significant differences in clusterin levels were found in any brain region between AD patients possessing different numbers of the ApoE4 allele.
|
9878186 |
1998 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Clusterin (apolipoprotein J), a multifunctional protein involved in amyloidogenesis in Alzheimer's disease, was studied immunohistochemically in both human transmissible spongiform encephalopathies (TSEs) and a mouse model of human TSE.
|
11907798 |
2002 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
LHGDN |
Clusterin is a glycosylated protein, and an alteration of its glycosylation in Alzheimer's disease might influence accurate quantification in cerebrospinal fluid through interference of antibody binding to the protein.
|
16490286 |
2006 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
AAPs, such as apolipoprotein E (ApoE) or apolipoprotein J (ApoJ) have been strongly implicated in the pathogenesis of AD in vitro and in vivo.
|
16972883 |
2006 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.
|
19734902 |
2009 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.
|
19734902 |
2009 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.
|
19734902 |
2009 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.
|
19734902 |
2009 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Previous biological studies support roles of CLU and CR1 in the clearance of beta amyloid (Abeta) peptide, the principal constituent of amyloid plaques, which are one of the major brain lesions of individuals with Alzheimer's disease.
|
19734903 |
2009 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASDB |
Previous biological studies support roles of CLU and CR1 in the clearance of beta amyloid (Abeta) peptide, the principal constituent of amyloid plaques, which are one of the major brain lesions of individuals with Alzheimer's disease.
|
19734903 |
2009 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
CTD_human |
Previous biological studies support roles of CLU and CR1 in the clearance of beta amyloid (Abeta) peptide, the principal constituent of amyloid plaques, which are one of the major brain lesions of individuals with Alzheimer's disease.
|
19734903 |
2009 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Previous biological studies support roles of CLU and CR1 in the clearance of beta amyloid (Abeta) peptide, the principal constituent of amyloid plaques, which are one of the major brain lesions of individuals with Alzheimer's disease.
|
19734903 |
2009 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The recent discoveries in genome-wide association studies (GWAS) of novel susceptibility loci (CLU, CR1 and PICALM) for Alzheimer's disease (AD) have elicited considerable interest in the AD community.
|
20080314 |
2010 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Genetic variability in CLU and its association with Alzheimer's disease.
|
20209083 |
2010 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals.
|
20534741 |
2010 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Replication of CLU, CR1, and PICALM associations with alzheimer disease.
|
20554627 |
2010 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Association of CLU and PICALM variants with Alzheimer's disease.
|
20570404 |
2012 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recently, two genome-wide association studies have identified three variants in CLU gene encoding clusterin associated with AD risk in Caucasians, while there are no studies on the association of CLU with AD risk in Asians.
|
20599866 |
2010 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Clusterin/apolipoprotein J was associated with atrophy of the entorhinal cortex, baseline disease severity, and rapid clinical progression in AD.
|
20603455 |
2010 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Unadjusted, CLU (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.85-0.96 for single-nucleotide polymorphism [SNP] rs11136000), CR1 (OR, 1.14; 95% CI, 1.07-1.22; SNP rs3818361), and PICALM (OR, 0.89; 95% CI, 0.84-0.94, SNP rs3851179) were associated with AD in white individuals.
|
20697030 |
2010 |